Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 169,673,296
  • Shares Outstanding, K 2,741,530
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.84
  • Price/Sales 4.31
  • Price/Cash Flow 10.79
  • Price/Book 4.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.87 +0.03%
on 04/21/17
64.15 -3.52%
on 04/05/17
-2.02 (-3.16%)
since 03/21/17
3-Month
60.54 +2.23%
on 01/26/17
66.80 -7.35%
on 03/01/17
-0.64 (-1.02%)
since 01/20/17
52-Week
53.06 +16.64%
on 05/06/16
66.80 -7.35%
on 03/01/17
+5.29 (+9.35%)
since 04/21/16

Most Recent Stories

More News
FDA approves 2nd near-copy of Remicade for immune disorders

Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.

JNJ : 121.76 (-0.09%)
MRK : 61.89 (-1.06%)
PFE : 33.64 (-0.30%)
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria

MO : 71.47 (+0.08%)
HON : 127.08 (+2.67%)
BRK.B : 163.41 (-0.95%)
MRK : 61.89 (-1.06%)
ORCL : 44.43 (-0.22%)
Global Monoclonal Antibody Therapeutics Market: Emergence of New Products to Generate Growth Opportunities for Players

ALBANY, New York, April 20, 2017 /PRNewswire/ --

BAYRY : 113.1000 (+0.93%)
MRK : 61.89 (-1.06%)
NVS : 73.40 (-0.30%)
GSK : 40.78 (+0.17%)
PFE : 33.64 (-0.30%)
Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa

Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness...

MRK : 61.89 (-1.06%)
Global Monoclonal Antibody Therapeutics Market: Emergence of New Products to Generate Growth Opportunities for Players

The global market for Monoclonal Antibody Therapeutics is expected to witness a high level of competition in the next few years, thanks to the rising number of players entering the market, states a research...

BAYRY : 113.1000 (+0.93%)
MRK : 61.89 (-1.06%)
NVS : 73.40 (-0.30%)
GSK : 40.78 (+0.17%)
PFE : 33.64 (-0.30%)
Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius® Bioreactors

- Sizes range from 3-liter bench-top to 1000-liter manufacturing scale

MRK : 61.89 (-1.06%)
Top Research Reports for Today: BRK.B, ORCL, MRK

Top Research Reports for Today: BRK.B, ORCL, MRK

DD : 78.65 (+0.46%)
MO : 71.47 (+0.08%)
HON : 127.08 (+2.67%)
MRK : 61.89 (-1.06%)
BRK.B : 163.41 (-0.95%)
ORCL : 44.43 (-0.22%)
Is J&J's Pharma Sales Slowdown a Warning for Other Players?

Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

JNJ : 121.76 (-0.09%)
MRK : 61.89 (-1.06%)
AMGN : 160.41 (-1.01%)
PFE : 33.64 (-0.30%)
SNY : 44.09 (-1.56%)
BMY : 53.48 (+0.07%)
Global Diabetic Therapeutic Market 2017-2021: The Strong Potential of Biologics - Leading Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk & Sanofi - Research and Markets

Research and Markets has announced the addition of the "Global Diabetic Therapeutic Market 2017-2021" report to their offering.

NVO : 35.88 (-1.43%)
MRK : 61.89 (-1.06%)
LLY : 81.89 (-0.06%)
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis

MKGAY : 36.6800 (-1.00%)
MRK : 61.89 (-1.06%)
NVS : 73.40 (-0.30%)
ESALF : 51.7500 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 62.89
1st Resistance Point 62.39
Last Price 61.89
1st Support Level 61.63
2nd Support Level 61.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.